GlassScriptPhysician profile
Celine Asef
NPI 1760165260
$1,486.59
in general payments reported to CMS, 2019-2025
13 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $451.13 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $212.25 | 2025 | Verquvo, Capvaxive |
| Regeneron Healthcare Solutions, INC. | $158.89 | 2025 | Dupixent, Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.91 | 2025 | Jardiance |
| Novo Nordisk INC | $152.48 | 2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $111.32 | 2025 | Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $79.67 | 2025 | |
| Chiesi USA, INC. | $43.54 | 2025 | Kengreal |
| Boston Scientific Corporation | $39.77 | 2025 | Avvigo Guidance System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $25.23 | 2025 | |
| Bridgebio Pharma, INC. | $20.95 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $20.64 | 2025 | Arexvy |
| Esperion Therapeutics, INC. | $14.81 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Asef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.